For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of this treatment and Tafamidis meglumine represents a significant advancement . These innovative therapies stabilize the transthyretin protein, slowing its destructive build-up and lessening the impact of the disease . People are now seeing